

BIOGEN INC.  
Form FWP  
September 11, 2015

Filed pursuant to Rule 433  
Registration No.: 333-206799  
September 10, 2015

**Biogen Inc.**

**\$1,500,000,000 2.900% Senior Notes Due 2020**

**\$1,000,000,000 3.625% Senior Notes Due 2022**

**\$1,750,000,000 4.050% Senior Notes Due 2025**

**\$1,750,000,000 5.200% Senior Notes Due 2045**

**PRICING TERM SHEET**

**2.900% Senior Notes Due 2020**

Issuer	Biogen Inc.
Principal Amount	\$1,500,000,000
Maturity Date	September 15, 2020
Issue Price (Price to Public)	99.792%
Interest Rate	2.900% per annum beginning on the Issue Date
Interest Payment Dates	Semi-annually, each March 15 and September 15, commencing March 15, 2016
Treasury Benchmark	1.375% due August 31, 2020
Spread to Benchmark Treasury	140 bps
Benchmark Treasury Yield	1.545%
Yield to Maturity	2.945%
Optional Redemption	Make whole call as set forth in the preliminary prospectus supplement (treasury rate plus 20 basis points)
CUSIP/ISIN:	09062X AC7 / US09062XAC74 <b>3.625% Senior Notes Due 2022</b>

Edgar Filing: BIOGEN INC. - Form FWP

Issuer	Biogen Inc.
Principal Amount	\$1,000,000,000
Maturity Date	September 15, 2022
Issue Price (Price to Public)	99.920%
Interest Rate	3.625% per annum beginning on the Issue Date
Interest Payment Dates	Semi-annually, each March 15 and September 15, commencing March 15, 2016
Treasury Benchmark	1.875% due August 31, 2022
Spread to Benchmark Treasury	170 bps

Benchmark Treasury Yield	1.938%
Yield to Maturity	3.638%
Optional Redemption	Make whole call as set forth in the preliminary prospectus supplement (treasury rate plus 25 basis points)
CUSIP/ISIN:	09062X AE3 / US09062XAE31 <b>4.050% Senior Notes Due 2025</b>
Issuer	Biogen Inc.
Principal Amount	\$1,750,000,000
Maturity Date	September 15, 2025
Issue Price (Price to Public)	99.764%
Interest Rate	4.050% per annum beginning on the Issue Date
Interest Payment Dates	Semi-annually, each March 15 and September 15, commencing March 15, 2016
Treasury Benchmark	2.000% due August 15, 2025
Spread to Benchmark Treasury	185 bps
Benchmark Treasury Yield	2.229%
Yield to Maturity	4.079%
Optional Redemption	Make whole call, in whole or in part, as set forth in the preliminary prospectus supplement (treasury rate plus 30 basis points) at any time prior to June 15, 2025 (three months prior to the maturity date of the notes due 2025)
	Par call, in whole or in part, at any time on or after June 15, 2025 (three months prior to the maturity date of the notes due 2025)
CUSIP/ISIN:	09062X AF0 / US09062XAF06 <b>5.200% Senior Notes Due 2045</b>
Issuer	Biogen Inc.
Principal Amount	\$1,750,000,000

Edgar Filing: BIOGEN INC. - Form FWP

Maturity Date	September 15, 2045
Issue Price (Price to Public)	99.294%
Interest Rate	5.200% per annum beginning on the Issue Date
Interest Payment Dates	Semi-annually, each March 15 and September 15, commencing March 15, 2016

Treasury Benchmark	3.000% due May 15, 2045
Spread to Benchmark Treasury	225 bps
Benchmark Treasury Yield	2.997%
Yield to Maturity	5.247%
Optional Redemption	Make whole call, in whole or in part, as set forth in the preliminary prospectus supplement (treasury rate plus 35 basis points) at any time prior to March 15, 2045 (six months prior to the maturity date of the notes due 2045)
	Par call, in whole or in part, at any time on or after March 15, 2045 (six months prior to the maturity date of the notes due 2045)
CUSIP/ISIN:	09062X AD5 / US09062XAD57
	<b>Terms Applicable to All Tranches</b>
Ratings	Baa1 / A- (Moody / S&P)
Trade Date	September 10, 2015
Original Issue Date (Settlement)	September 15, 2015
Change of Control	Upon the occurrence of a Change of Control Triggering Event (as defined in the preliminary prospectus supplement to which this pricing term sheet relates), Biogen Inc. will be required to make an offer to purchase the notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to but not including the date of repurchase
Minimum Denomination	\$2,000 and integral multiples of \$1,000 in excess thereof
Joint Book-Running Managers	Goldman, Sachs & Co. Merrill Lynch, Pierce, Fenner & Smith Incorporated
Passive Bookrunners	Credit Suisse Securities (USA) LLC ( <i>Notes due 2045</i> ) Deutsche Bank Securities Inc. ( <i>Notes due 2025</i> ) J.P. Morgan Securities LLC ( <i>Notes due 2020</i> )

Edgar Filing: BIOGEN INC. - Form FWP

Mitsubishi UFJ Securities (USA), Inc. (*Notes due 2022*)

Morgan Stanley & Co. LLC (*Notes due 2020, 2022, 2025, 2045*)

Senior Co-Managers

Credit Suisse Securities (USA) LLC

Deutsche Bank Securities Inc.

J.P. Morgan Securities LLC

Mitsubishi UFJ Securities (USA), Inc.

Co-Managers

HSBC Securities (USA) Inc.

Mizuho Securities USA Inc.

U.S. Bancorp Investments, Inc.

*None of the securities ratings is a recommendation to buy, sell or hold the notes. Each rating may be subject to revision or withdrawal at any time, and should be evaluated independently of any other rating.*

*The issuer has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the Securities and Exchange Commission ( SEC ) for the offerings to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and these offerings. You may get these documents for free by visiting EDGAR on the SEC Web site at [www.sec.gov](http://www.sec.gov). Alternatively, the issuer, any underwriter or any dealer participating in the offerings will arrange to send you the prospectus if you request it by calling Goldman, Sachs & Co. toll free at 1 (866) 471-2526 or Merrill Lynch, Pierce, Fenner & Smith Incorporated toll free at 1 (800) 294-1322.*

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED (OTHER THAN ANY STATEMENT RELATING TO THE IDENTITY OF THE LEGAL ENTITY AUTHORIZING OR SENDING THIS COMMUNICATION IN A NON-US JURISDICTION). SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION HAVING BEEN SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.